AU2001262996A1 - Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum - Google Patents
Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparumInfo
- Publication number
- AU2001262996A1 AU2001262996A1 AU2001262996A AU6299601A AU2001262996A1 AU 2001262996 A1 AU2001262996 A1 AU 2001262996A1 AU 2001262996 A AU2001262996 A AU 2001262996A AU 6299601 A AU6299601 A AU 6299601A AU 2001262996 A1 AU2001262996 A1 AU 2001262996A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- plasmodium falciparum
- malaria vaccine
- antigenic domain
- novel antigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000223960 Plasmodium falciparum Species 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 229940124735 malaria vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20243000P | 2000-05-08 | 2000-05-08 | |
| US60202430 | 2000-05-08 | ||
| PCT/US2001/014716 WO2001085927A1 (en) | 2000-05-08 | 2001-05-08 | Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001262996A1 true AU2001262996A1 (en) | 2001-11-20 |
Family
ID=22749836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001262996A Abandoned AU2001262996A1 (en) | 2000-05-08 | 2001-05-08 | Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001262996A1 (en) |
| WO (1) | WO2001085927A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10249390A1 (en) * | 2002-10-23 | 2004-05-13 | Ruprecht-Karls-Universität Heidelberg | Recombinant MVA strains as potential vaccines against P. falciparum malaria |
| WO2004043399A2 (en) * | 2002-11-13 | 2004-05-27 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| JP2000504223A (en) * | 1996-01-29 | 2000-04-11 | ジョージタウン・ユニヴァーシティ | Malaria vaccine based on the addition of MSA1 peptide |
-
2001
- 2001-05-08 AU AU2001262996A patent/AU2001262996A1/en not_active Abandoned
- 2001-05-08 WO PCT/US2001/014716 patent/WO2001085927A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001085927A1 (en) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1309602A4 (en) | Malaria immunogen and vaccine | |
| IL151942A0 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
| AU2001241918A1 (en) | Methods of enhancing activity of vaccines and vaccine compositions | |
| AU2003208986A1 (en) | Inactivation of west nile virus and plasmodium falciparum using alloxazine-derivating photosensitizers | |
| EP1569950B8 (en) | Plasmodium falciparum antigens and methods of use | |
| AU2002343321A1 (en) | Isolation and purification of plasmodium falciparum merozoite protein-142 | |
| AU2002326751A1 (en) | Immunoglobulin e vaccines and methods of use thereof | |
| AU2002331791A1 (en) | Methods of preparing improved water-soluble extracts containing antioxidants and uses thereof | |
| AU2001292667A1 (en) | Immunogenic composition of hepatitis c and methods of use thereof | |
| AU2001295672A1 (en) | Vaccine composition and stabilisation method | |
| AU2001262996A1 (en) | Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum | |
| AU2002228347A1 (en) | Malaria plasmodium antigen polypeptide SE36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen | |
| AU2002361718A8 (en) | Oxidized fungal antigens and methods of making and using thereof | |
| AU2003291476A8 (en) | Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide | |
| AU2002347464A1 (en) | Anti-arthropod vector vaccines methods of selecting and uses thereof | |
| AU2002304480A1 (en) | Plasmodium falciparum antigens and vaccine and diagnostic uses thereof | |
| DE60220988D1 (en) | PREPARATION AND USE OF A PLASMODIUM FUSIONANT | |
| DK1697405T3 (en) | LSA-5 liver stage and blood stage antigen from Plasmodium falciparum, immunogenic preparation comprising this antigen and vaccines against malaria | |
| AU1762092A (en) | Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria | |
| HK1097277A (en) | Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria | |
| AU2003281909A1 (en) | Method of obtaining conjugate vaccines and vaccine compositions containing same | |
| AU2002366708A8 (en) | Preparation of vaccines using photosensitizer and light | |
| AUPR020900A0 (en) | Vaccines and methods of vaccination | |
| AU2003210719A1 (en) | Identification of mutant antigens with enhanced immunogenicity | |
| AU2001261213A1 (en) | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof |